Related references
Note: Only part of the references are listed.Targeting NOTCH1 in T-ALL: Starving the dragon
Daniel Herranz et al.
CELL CYCLE (2016)
The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eμ-TCL1 mouse model
Matthew D. Blunt et al.
BLOOD (2015)
Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia
Benedito A. Carneiro et al.
CANCER BIOLOGY & THERAPY (2015)
Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells
Huibo Li et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2015)
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
G. S. Choudhary et al.
CELL DEATH & DISEASE (2015)
Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase
Marco Colamonici et al.
ONCOTARGET (2015)
Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia
Alice Cani et al.
ONCOTARGET (2015)
The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia
Matteo Allegretti et al.
SCIENTIFIC REPORTS (2015)
FAK Mediates a Compensatory Survival Signal Parallel to PI3K-AKT in PTEN-Null T-ALL Cells
Dewen You et al.
CELL REPORTS (2015)
Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia
N. Sandhoefer et al.
LEUKEMIA (2015)
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia
Francesca Chiarini et al.
Oncotarget (2015)
mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells
Brandon R. Beagle et al.
ONCOTARGET (2015)
IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells
Shuai Dong et al.
BLOOD (2014)
Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis
Wei Ding et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation
Seiichi Okabe et al.
CANCER BIOLOGY & THERAPY (2014)
Autophagy Is a Survival Mechanism of Acute Myelogenous Leukemia Precursors during Dual mTORC2/mTORC1 Targeting
Jessica K. Altman et al.
CLINICAL CANCER RESEARCH (2014)
Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph plus acute lymphoblastic leukemia cells
Xi Yang et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells
Weiguo Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia
V. El-Khoury et al.
LEUKEMIA (2014)
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
K. G. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells
Takayuki Hoshii et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia
Leyuan Ma et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies
Jan A. Burger et al.
SEMINARS IN CANCER BIOLOGY (2014)
A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor
Russell T. Burke et al.
ONCOTARGET (2014)
Mechanistic/mammalian target protein of rapamycin signaling in hematopoietic stem cells and leukemia
Atsushi Hirao et al.
CANCER SCIENCE (2013)
Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia
Tomasz Stoklosa et al.
EXPERIMENTAL HEMATOLOGY (2013)
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia
Camilla Evangelisti et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2013)
Toward a NOTCH1/FBXW7/RAS/PTEN-Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study
Amelie Trinquand et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Combined inhibition of the phosphoinosityl-3-kinase (PI3Kinase) P110δ subunit and mitogen-extracellular activated protein kinase (MEKinase) shows synergistic cytotoxicity against human acute myeloid leukemia progenitors
Yan Xing et al.
LEUKEMIA RESEARCH (2013)
The evolution of the TOR pathway and its role in cancer
E. M. Beauchamp et al.
ONCOGENE (2013)
Regulatory Effects of Sestrin 3 (SESN3) in BCR-ABL Expressing Cells
Eliza Vakana et al.
PLOS ONE (2013)
Inhibition of PI3K/mTOR Overcomes Nilotinib Resistance in BCR-ABL1 Positive Leukemia Cells through Translational Down-Regulation of MDM2
Jie Ding et al.
PLOS ONE (2013)
PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor
K. Airiau et al.
CELL DEATH & DISEASE (2013)
Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia
Sarah K. Tasian et al.
BLOOD (2012)
Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment
Zhihong Zeng et al.
BLOOD (2012)
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
Shannon L. Maude et al.
BLOOD (2012)
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107)
Sergio Amadori et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
An overview of the mTOR pathway as a target in cancer therapy
Ryan D. Gentzler et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for vertical and lateral combination strategies
Maria Rosaria Ricciardi et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2012)
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
Brian J. Lannutti et al.
BLOOD (2011)
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
Julia Hoellenriegel et al.
BLOOD (2011)
Activation of mTORC2 by Association with the Ribosome
Vittoria Zinzalla et al.
CELL (2011)
Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors
Jessica K. Altman et al.
CLINICAL CANCER RESEARCH (2011)
High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling
Hind Medyouf et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance
Hilmar Quentmeier et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL
Amanda J. Redig et al.
LEUKEMIA & LYMPHOMA (2011)
mTOR: from growth signal integration to cancer, diabetes and ageing
Roberto Zoncu et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo
K. Schuster et al.
BLOOD CANCER JOURNAL (2011)
Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells
Eliza Vakana et al.
AUTOPHAGY (2010)
Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia
Nicolas Chapuis et al.
CLINICAL CANCER RESEARCH (2010)
Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition
Jianguo Zhuang et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Critical roles for mTORC2-and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells
Nathalie Carayol et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia
Alejandro Gutierrez et al.
BLOOD (2009)
A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia
Alexander E. Perl et al.
CLINICAL CANCER RESEARCH (2009)
CSL-MAML-dependent Notch1 signaling controls T lineage-specific IL-7Rα gene expression in early human thymopoiesis and leukemia
Sara Gonzalez-Garcia et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells
Rami Hayun et al.
LEUKEMIA & LYMPHOMA (2009)
Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor
Chikara Hirase et al.
LEUKEMIA RESEARCH (2009)
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia.
Charles G. Mullighan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia
David T. Teachey et al.
BLOOD (2008)
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies
David A. Rizzieri et al.
CLINICAL CANCER RESEARCH (2008)
PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability
Ana Silva et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Lack of antileukemic activity of rapamycin in elderly patients with acute myeloid leukemia evolving from a myelodysplastic syndrome
Fernando Callera et al.
LEUKEMIA RESEARCH (2008)
Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia
C. Sillaber et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2008)
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia
Teresa Palomero et al.
NATURE MEDICINE (2007)
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients
Jerome Tamburini et al.
BLOOD (2007)
Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia
Steven M. Chan et al.
BLOOD (2007)
Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts
P. L. Tazzari et al.
LEUKEMIA (2007)
TOR signaling in growth and metabolism
S Wullschleger et al.
CELL (2006)
The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL
DT Teachey et al.
BLOOD (2006)
TOR signaling in growth and metabolism
Stephan Wullschleger et al.
CELL (2006)
Differential regulation of the p70 S6 kinase pathway by interferon αt (IFNα) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells
S Parmar et al.
BLOOD (2005)
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
A Burchert et al.
LEUKEMIA (2005)
Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells
R Avellino et al.
BLOOD (2005)
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia
AP Weng et al.
SCIENCE (2004)
Survival of acute myeloid leukemia cells requires PI3 kinase activation
Q Xu et al.
BLOOD (2003)
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
SM Graham et al.
BLOOD (2002)
Share Paper
